Myriad Genetics, Inc. (MYGN: Quote) said that Noridian Administrative Services LLC, Medicare administrative contractor for Jurisdiction F that includes Utah, has priced the new molecular pathology codes for calendar year 2013. As all of Myriad’s tests reimbursed by Medicare are performed in its Utah laboratory, these rates would be applicable for Myriad’s Medicare reimbursement this year.
For fiscal 2013, the company said it currently sees total revenues to be at the high end of the $575 million – $585 million prior guidance range and earnings per share to be at the high end of the $1.55 – $1.58 previous outlook range.
Click here to receive FREE breaking news email alerts for Myriad Genetics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News